Citations

Clear

400 citation(s) found for "Sm, Berry".

Autoimmune progesterone dermatitis: a retrospective case series
Aghazadeh, Nessa , Berry, Nicholas A. , Torgerson, Rochelle R. , Park, Miguel A., Davis, Dawn Marie R. , Aghazadeh Mohandesi, Nessa

Mayo Clinic

International Journal of Women’s Dermatology | July 8, 2022 | Volume: 8 | Issue: 3 | Pages: e009

10.1097/jw9.0000000000000009 | PMID 35822192 Get It

Background: Autoimmune progesterone dermatitis (APD) is a rare hypersensitivity disorder characterized by recurring dermatologic manifestations during the luteal phase of the menstrual cycle in women. Well-defined clinical and diagnostic criteria, outcomes measurements, and standard treatments are lacking. Methods: We performed a single-institution retrospective review of adult patients (older than 20 years at the time of diagnosis) with APD. Results: Fourteen patients were included with mean age of clinical onset of 34.3 ± 7.7 (range 24-54) years. There was a delay of 3.9 ± 5.5 (range 0.4-20) years between the onset of disease symptoms and diagnosis. The onset of APD was after exposure to exogenous progesterone in 9 of 14 patients. Progesterone skin test was performed in 9 patients and 6 were positive. Patients frequently presented with urticaria (9/14, 64.3%) and dermatitis (4/14, 28.6%). Continuous combined oral contraceptives (4/14, 28.6%), gonadotropin-releasing hormone agonist (3/14, 21.4%), and hysterectomy with bilateral salpingo-oophorectomy (2/14, 14.3%) were the most common attempted treatments with reliable outcomes. Conclusions: APD is a rare disorder which lacks universal diagnostic measures and criteria, contributing to a significant delay in diagnosis. Large-scale multicenter studies are needed to develop accurate tests, establish diagnostic criteria, and define treatment outcomes.
Modular Fluted Tapered Stems for Periprosthetic Femoral Fractures
Hannon, Charles P. , Sheehan, Kevin , Duong, Stephanie Q. , Yuan, Brandon J. , Lewallen, David G. , Berry, Daniel J. , Abdel, Matthew P. , Sheehan, Kevin P , Abdel, Matthew P , Yuan, Brandon , Berry, Daniel J , Hannon, Charles P

Mayo Clinic

Journal of Bone and Joint Surgery | July 6, 2022 | Volume: 104 | Issue: 13 | Pages: 1188-1196

10.2106/jbjs.21.01168 | PMID 35793797 Get It

Background: Modular fluted tapered (MFT) stems have advanced treatment of Vancouver B 2 and B 3 periprosthetic femoral fractures, but series to date have been limited with respect to cohort size and follow-up duration. The purpose of this study was to determine implant survivorship, radiographic results, complications, and clinical outcomes of Vancouver B 2 and B 3 periprosthetic femoral fractures treated with MFT stems in a large series of patients. Methods: We identified 171 Vancouver B 2 (109) and B 3 (62) periprosthetic femoral fractures treated with an MFT stem between 2000 and 2018 using our institutional total joint registry. The mean age was 75 years, 50% were female, and the mean body mass index was 29 kg/m 2 . The median stem diameter was 18 mm and median stem length was 210 mm. The cumulative incidences of revision and reoperation with death as the competing risk were calculated, radiographs were reviewed, and clinical outcomes were evaluated using the Harris hip score (HHS). The mean follow-up was 5 years. Results: The 10-year cumulative incidence of any revision was 10%. There were 17 revisions, of which only 3 were for the distal fluted portion of the MFT stem. Revision indications included periprosthetic joint infection (PJI) (n = 6) and dislocation (n = 11). The 10-year cumulative incidence of any reoperation was 15%. In addition to the above 17 revisions, there were 7 reoperations for superficial wound complications (n = 4), Vancouver B 1 periprosthetic femoral fracture (n = 1), vascular occlusion (n = 1), and acetabular cartilage degeneration requiring an acetabular component (n = 1). Radiographically, there was 1 fracture nonunion. All unrevised MFT stems were radiographically well fixed. Subsidence of ≥5 mm occurred in 11%, but all implants were stable at the most recent follow-up. The mean HHS was 75 at 2 years (n = 71). Conclusions: In this large series of 171 Vancouver B 2 and B 3 periprosthetic femoral fractures treated with MFT stems, we found that such constructs were associated with a high rate of fracture healing and provided extremely reliable and durable implant fixation, with no revisions for aseptic loosening. Dislocation and PJI were the most common complications. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Spinal Compared with General Anesthesia in Contemporary Primary Total Hip Arthroplasties
Owen, Aaron R. , Amundson, Adam W. , Fruth, Kristin M. , Duncan, Christopher M. , Smith, Hugh M. , Johnson, Rebecca L. , Taunton, Michael J. , Pagnano, Mark W. , Berry, Daniel J. , Abdel, Matthew P. , Abdel, Matthew P , Johnson, Rebecca L , Taunton, Michael J , Berry, Daniel J , Fruth, Kristin M

Mayo Clinic

Journal of Bone and Joint Surgery | June 21, 2022 | Volume: 104 | Issue: 17 | Pages: 1542-1547

10.2106/jbjs.22.00280 | PMID 35726967 Get It

Background: The specific advantages of spinal anesthesia compared with general anesthesia for primary total hip arthroplasty (THA) remains unknown. Therefore, this study aimed to investigate the pain control, length of stay, and postoperative outcomes associated with spinal anesthesia compared with general anesthesia in a large cohort of primary THAs from a single, high-volume academic institution. Methods: We retrospectively identified 13,730 primary THAs (11,319 patients) from 2001 to 2016 using our total joint registry. Of these cases, 58% had general anesthesia and 42% had spinal anesthesia. The demographic characteristics were similar between groups, with mean age of 64 years, 51% female, and mean body mass index (BMI) of 31 kg/m 2 . Data were analyzed using an inverse probability of treatment weighted model based on a propensity score that accounted for numerous patient and operative factors. The mean follow-up was 6 years. Results: Patients treated with spinal anesthesia had lower Numeric Pain Rating Scale (NPRS) scores (p < 0.001) and required fewer postoperative oral morphine equivalents (OMEs) at all time points evaluated (p < 0.001). Patients treated with spinal anesthesia also had shorter hospital length of stay (p = 0.02), fewer altered mental status events (odds ratio [OR], 0.7; p = 0.02), and fewer intensive care unit (ICU) admissions (OR, 0.7; p = 0.01). There was no difference in the incidence of deep vein thrombosis (p = 0.8), pulmonary embolism (p = 0.4), 30-day readmissions (p = 0.17), 90-day readmissions (p = 0.18), all-cause revisions (p = 0.17), or all-cause reoperations (p = 0.14). Conclusions: In this large, single-institution study, we found that spinal anesthesia was associated with reduced pain scores and OME use postoperatively. Furthermore, spinal anesthesia resulted in fewer altered mental status events and ICU admissions. These data favor the use of spinal anesthesia in primary THAs. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Creation of a Total Hip Arthroplasty Patient-Specific Dislocation Risk Calculator
Wyles, Cody C. , Kremers, Hilal Maradit , Larson, Dirk R. , Lewallen, David G. , Taunton, Michael J. , Trousdale, Robert T. , Pagnano, Mark W. , Berry, Daniel J. , Sierra, Rafael J. , Maradit-Kremers, Hilal, Sierra, Rafael J , Larson, Dirk , Maradit Kremers, Hilal , Taunton, Michael J , Wyles, Cody C , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | June 15, 2022 | Volume: 104 | Issue: 12 | Pages: 1068-1080

10.2106/jbjs.21.01171 | PMID 36149242 Get It

Background: Many risk factors have been described for dislocation following total hip arthroplasty (THA), yet a patient-specific risk assessment tool remains elusive. The purpose of this study was to develop a high-dimensional, patient-specific risk-stratification nomogram that allows dynamic risk modification based on operative decisions. Methods: In this study, 29,349 THAs, including 21,978 primary and 7371 revision cases, performed between 1998 and 2018 were evaluated. During a mean 6-year follow-up, 1521 THAs were followed by a dislocation. Patients were characterized, through individual-chart review, according to non-modifiable factors (demographics, indication for THA, spine disease, prior spine surgery, and neurologic disease) and modifiable operative decisions (operative approach, femoral head diameter, and type of acetabular liner [standard, elevated, constrained, or dual-mobility]). Multivariable regression models and nomograms were developed with dislocation as a binary outcome at 1 year and 5 years postoperatively. Results: Dislocation risk, based on patient-specific comorbidities and operative decisions, was wide-ranging—from 0.3% to 13% at 1 year and from 0.4% to 19% at 5 years after primary THA, and from 2% to 32% at 1 year and from 3% to 42% at 5 years after revision THA. In the primary-THA group, the direct anterior approach (hazard ratio [HR] = 0.27) and lateral approach (HR = 0.58) decreased the dislocation risk compared with the posterior approach. After adjusting for the approach in that group, the combination of a ≥36-mm-diameter femoral head and an elevated liner yielded the largest decrease in dislocation risk (HR = 0.28), followed by dual-mobility constructs (HR = 0.48). In the patients who underwent revision THA, the adjusted risk of dislocation was most markedly decreased by the use of a dual-mobility construct (HR = 0.40), followed by a ≥36-mm femoral head and an elevated liner (HR = 0.88). The adjusted risk of dislocation after revision THA was decreased by acetabular revision (HR = 0.58), irrespective of whether other components were revised. Conclusions: Our patient-specific dislocation risk calculator, which was strengthened by our use of a robust multivariable model that accounted for comorbidities associated with instability, demonstrated wide-ranging patient-specific risks based on comorbidity profiles. The resultant nomograms can be used as a screening tool to identify patients at high risk for dislocation following THA and to individualize operative decisions for evidence-based risk mitigation. Level of Evidence: Prognostic Level IV . See Instructions for Authors for a complete description of levels of evidence.
0147 Electrophysiologic Localization of Pathological Brain Tissue Is Accomplished with Intracranial Sleep Staging
Berry, Brent

Mayo Clinic

Sleep | May 31, 2022 | Volume: 45 | Issue: Supplement_1 | Pages: A67-A68

10.1093/sleep/zsac079.145 Get It

Abstract Introduction Low Frequency brain rhythms facilitate communication across large spatial regions in the brain and high frequency rhythms are thought to signify local processing among nearby assemblies. A heavily investigated mode by which these low frequency and high frequency phenomenon interact is Phase-Amplitude Coupling )PAC). This phenomenon has recently shown promise as a novel electrophysiologic biomarker, in a number of neurologic diseases. In 10 patients undergoing phase-2 monitoring for the evaluation of surgical resection and in whom temporal depth electrodes were implanted, we investigated electrophysiologic relationships of PAC in epileptogenic (seizure onset zone or SOZ) and non-epileptogenic tissue (non-SOZ). That this biomarker can differentiate pathologic from non-pathologic brain and has been established with ictal and pre-ictal data, but less so with interictal data. Here we show that this biomarker can differentiate interictally. We also show PAC activity is related to interictal epileptiform discharges and high frequency activity. Importantly, we also show a differential level of PAC in slow-wave-sleep from NREM1-2 and awake. And finally we show that localization of pathologic tissue sensitivity and specificity is optimal when utilizing beta or alpha phase onto high-gamma or Ripple with knowledge of the sleep stage. Illustrating some of the physiologic nature of this biomarker in human epilepsy will provide a basis for understanding the mechanism of neurologic disease and normal physiology of brain communication, details which are at this point ready to be utilized in neurotechnological therapies to treat and understand both. Methods Per Institutional Review Board protocol, 10 patients who were under evaluation for resective surgery for MRE at Mayo Clinic in Rochester MN were included in this study. IRB approved the study and necessary consenting procedures were followed prior to any data acquisition. All subjects had bilaterally placed intracranial depth electrodes with usually 8 contacts. In some cases not all contacts could be used for data acquisition (hardware or recording problems). 6 Subjects of this cohort had scalp and EMG recordings concurrently placed for the purposes of sleep scoring. Subject recordings were ignored for POD-1 as anesthetics were dissipating. Subjects then stayed in the ICU ranging from 3-12 days before explanation.Pathological tissue identified as seizure onset zone (SOZ) was determined from phase II monitoring and determined by a trained neurologist. Sleep staging was done with expert-in-the-loop semi automated methods described elsewhere but overseen by a trained neurologist. Behavioral state was determined with scalp EEG signals and verified by a neurologist board certified in sleep medicine. All EEG recordings were bandpass filtered 0.3-75Hz and 60Hz notch filtered for scoring. Visual sleep scoring was in accordance with standard methods with modification for replacing the electrooculogram (EOG) recording with FP1, FP2, FPZ scalp electrodes. Wakefulness was determined by the presence of eye blinks visualized in fronto-parietal scalp leads, accompanied by posteriorly dominant alpha rhythms (8 - 12 Hz) comprising &gt;50% of the epoch. Slow-wave sleep (N3) was scored when high-voltage (&gt;75 uV) delta (0.5 - 3 Hz) frequency scalp EEG activity was present in at least 20% of the epoch (i.e., at least 6 s within a 30 s epoch) in the frontal derivations using conventional International 10-20 System electrode placements (FP1, FP2, FZ, F3, F4, CZ, C3, C4, O1, O2, and Oz). Phase Amplitude Coupling with Coherency Angle CFC. A Hanning taper n points is the length of the sliding time window. Next, the coherency CFC(fmodulating,fmodulated) was estimated between signal {Xt} and the estimate of the time-course of power{Pt(fmodulated)} for a given frequency fmodulating. The coherence was the absolute value of the CFC . The phase difference between the signal at fmodualting and the power at fmodulated is given by the angle of the coherency arg(CFC). In this case γ refer to a 1024 points Hanning window and * to the complex conjugate. This allowed us to characterize the phase-to-power cross-frequency interaction with respect to f and fmodulated sensor by sensor. The spike detection algorithm was utlized to evaluated successive 1 minute blocks of iEEG and removes artifact channels. Individual channels were defined as average slope greater than 10 SD outside of mean slopes of all channels. Second, iEEG was bandpass filtered 20-50Hz to identify possible spikes, where a sharp discharge must last between 20-70ms. Absolute amplitudes of peaks greater than 4SD of channel mean amplitude were noted as potential spike locations for further consideration. Third, raw iEEG was bandpass filtered (2nd order Butterworth) 1-35Hz. A scaling factor is determined by finding a value that will bring the median of all channel amplitudes to 70uV. All channels are multiplied by this scaling factor. Once the data have been scaled, the amplitude and slope of each half-wave of the potential spikes identified previously in step 2 are calculated and the values are compared to static thresholds (Total amplitude of both half-waves &gt; 600μV, slope of each half-wave &gt; 7μV/ms, duration of each half-wave &gt; 10ms). Potential spikes with half-waves that exceed these thresholds are marked as interictal spikes.HFOs were detected using a Hilbert transform-based method, as previously reported. Here, the discrete time series is transformed into an analytic signal, where the real part is the original signal, and the imaginary part is the Hilbert transform of the original, x(t). Results Holding constant the frequency for amplitude to include all high activity (30-175Hz), beta is the best localizing (not statistically significant from alpha) band. Holding the frequency for phase, constant, there is no statistical difference between LG, HG, and ripple in terms of pathological bain tissue localization. Examining different frequencies for phase in varied behavioral/sleep states using 12 minute awake segments were used in all 10 patients, localization is best via AUROC when delta is the frequency band used to calculate PAC in Slow Wave Sleep / NREM3.Interictal Epileptiform spiking is seen with much higher regularity, although correlated and seen in the SOZ. A great deal of the associated elevations in wide-spectrum (0.5-30 modulating 65-175Hz) PAC (here defined as &gt;2 SD across the entire 2 hour period and assessed across all channels) occurred with IEDs. Since 3 second segments were used to calculate PAC values, sometimes 2 IEDs were within a single epoch although in a small minority of observations. PAC elevations are seen with IEDs and with HFO, although to a greater extend with spikes. However, some IEDs are not associated with elevations in PAC. In fact most detected IEDs were not associated with elevated PAC values or with HFOs for that matter. A minority of IEDs are associated with elevated PAC values and HFOs. At the group and individual levels the average spike count per patient, grouping all SOZ and non-SOZ electrodes together, there is not a statistically significant effect, but if the average count is taken per electrode within a single patient, a significant difference was noted at p = .0031. Subjects on average had 15 (SEM 0.15) electrodes and SOZ electrode counts of 3 (SEM 0.71). When analyzing IED + elevated PAC, grouped SOZ electrodes among patients and within individuals show a strongly significant effect (.0004). When taking into account electrode numbers within each group this significance only increases (.0001). At the individual level, significance of p&lt;0.05 is seen for all but one patient in this cohort. Conclusion Sleep Stage is critical in the analysis of pathological brain from non-pathological brain and electrophysiologic biomarkers behave differently in the different behavioral states. Here we found evidence to support his proposition in the following ways: low frequency delta phase modulates a broad high frequency amplitude in N3 and has relevance for brain pathology. Phase-Amplitude Coupling is increased in pathologic tissue. Peaks in PAC occur sporadically and infrequently in these patients. PAC is correlated with Interictal Epileptiform Discharges and High Frequency Oscillations however most Interictal Epileptiform Discharges are unrelated to peaks in Phase-Amplitude Coupling. Low Frequency Activity in Beta-band modulates broad high frequency power across low gamma, high gamma, and ripple bands. Support (If Any) Neurophysiological mapping and stimulation of the human brain for memory enhancement. Funded by EUO - PIS via BioTechMed Center, Department of Multimedia Systems, Faculty of Electronics, Telecommunication and Informatics, Gdansk University of Technology
Abstract 12924: CCL18 Promotes Effector Functions of Pro-Inflammatory Macrophages by Inactivating GSK-3β
Hu, Zhao‐Lan , Frye, Robert L. , Weyand, Cornelia M. , Zhao, Tuantuan V. , Berry, Gerald J. , Bernstein, Kenneth E. , Goronzy, Jörg J.

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.12924 Get It

Background: The risk for cardiovascular disease is multifold higher in patients with the autoimmune disease rheumatoid arthritis, but underlying mechanisms remain poorly defined. We have explored whether patients with rheumatoid arthritis (RA) and patients with coronary artery disease (CAD) share pro-inflammatory effector cells that sustain tissue inflammation, thus maintaining synovial inflammation and atherosclerotic plaque formation. Methods: Tissue cytokines expressed in RA synovial lesions were analyzed by cytokine array technology. Cytokine production in macrophages was verified with RT-PCR, immunohistochemistry and flow cytometry. Mitochondrial function was evaluated by Seahorse analyzer. Results: In highly inflamed synovial tissues, 21 of 60 cytokines tested were significantly elevated, with the small cytokine CCL18 being strongly associated with tissue inflammation. Immunohistochemical examination assigned CCL18 to CD68 + tissue macrophages in both the atherosclerotic plaque and in rheumatoid synovitis. In monocyte-derived macrophages (MΦ), CCL18 enhanced production of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α and stimulated production of the tissue-injurious enzyme cathepsin K. Pro-inflammatory effector functions were linked to CCL18 induced activation of mitochondrial metabolism, quantified by oxygen consumption rates and generation of ATP. Macrophage stimulation with recombinant CCL18 resulted in the inactivating phosphorylation of the metabolic sensor GSK-3β. Immunoprecipitation experiments localized GSK-3β to the mitochondrial surface and imaging studies revealed excessive formation of mitochondria-endoplasmic reticulum connections in patient-derived CCL18 hi macrophages. Conclusions: Pro-inflammatory MΦ in CAD and RA patients share a metabolic profile of increased mitochondrial oxygen consumption and ATP production. Mitochondrial activation depends on inactivation of the metabolic sensor GSK-3β and promote pro-inflammatory effector functions, such as production of cytokines and proteases. Inhibiting GSK-3β activation provides a novel therapeutic strategy to suppress pro-inflammatory macrophages in CAD and RA.
Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Potter, David A. , Roesch, Erin , Lu, Ruixiao , Samson, Susan, Stafford, Debra, Albain, Kathy S. , Chien, A. Jo , Perlmutter, Jane , Melisko, Michelle , Veer, Laura van ‘t , Wilson, Amy , Asare, Smita , Berry, Donald A. , Schwab, Richard B. , Potter, David A , Yau, Christina , Wolf, Denise M. , Isaacs, Claudine , Trivedi, Meghana V. , Yee, Douglas , Boughey, Judy C. , Thomas, Alexandra , Hylton, Nola M. , Li, Wen , DeMichele, Angela , Symmans, W. Fraser , Hershman, Dawn L. , Veer, Laura J. van’t , Rugo, Hope S. , Esserman, Laura J.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: PD8-07-PD8-07

10.1158/1538-7445.sabcs21-pd8-07 Get It

Abstract Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint (MP) risk to evaluate novel agents as neoadjuvant therapy for women with high-risk breast cancer. Tucatinib is a potent HER2 (ErbB2) tyrosine kinase inhibitor, selective for HER2 vs. epidermal growth factor receptor (EGFR) and is active vs. brain metastases. Safety and efficacy of tucatinib combined with paclitaxel, pertuzumab, and trastuzumab are unknown and were tested in a planned 10 patient (pt) safety run-in of the I-SPY 2 trial. Methods: Women with tumors ≥ 2.5cm were eligible for screening. Only pts with tumors that were HER2+ by FISH were eligible for this treatment. Treatment included tucatinib (max dose 300 mg) BID for 12 weeks with weekly paclitaxel 80 mg/m2 and trastuzumab (2 mg/kg weekly following loading), and pertuzumab (420 mg every 3 weeks following loading), followed by doxorubicin/cyclophosphamide (AC) every 2 weeks x 4. The control arm was weekly paclitaxel and trastuzumab with pertuzumab for 12 weeks followed by AC every 2 weeks x 4. All pts undergo serial MR imaging and response at 3 & 12 weeks is combined with real time pCR data to estimate, and continuously update, the predicted pCR rate for each trial arm. The goal of the trial is to identify/graduate regimens with ≥85.% Bayesian predictive probability of success (i.e. demonstrating superiority to control) in a future 300-patient phase 3 neoadjuvant trial with a pCR endpoint. This run-in arm was conducted to determine safety of combining tucatinib with paclitaxel/trastuzumab/pertuzumab, monitoring special adverse events of interest including LFT elevations and gastrointestinal toxicities.Methods: The I-SPY 2 methods have been previously published. Results: 20 pts were evaluable in tucatinib treatment arm. The control arm included 329 historical controls enrolled since April 2010. The initial tucatinib dose was 300 mg BID. After enrollment of the first 8 pts, there were 3 pts with grade 3 LFT elevations, 2 pts with grade 2/3 diarrhea, 1 pt with grade 2 neutropenia, and 1 pt with grade 3 nausea. After this safety review, the tucatinib dose was lowered to 250 mg BID. Among 5 additional pts enrolled, 3 developed grade 2/3 LFT abnormalities. The protocol was then modified to tucatinib 150 mg BID days 1-28 and then 250 mg BID days 29-84; 7 pts were treated. Safety data were reviewed after 20 pts were enrolled; the arm was then suspended due to similar LFT elevations regardless of tucatinib dose reduction or schedule. 7 of 20 pts (35%) had reversible Grade 3 or higher ALT/AST elevation (Table). No pt met criteria for Hy’s Law. In terms of efficacy, 12 of 14 evaluable pts had &gt; 80% reduction of tumor volume by 12 weeks, measured by MRI assessment of functional tumor volume (FTV). Conclusion: The goal of the run-in arm was to determine the safety of adding tucatinib to the combination of paclitaxel/trastuzumab/pertuzumab. The addition of tucatinib resulted in unacceptable but reversible LFT elevations despite tucatinib dose reduction. Tucatinib containing therapy resulted in &gt;80% decline in tumor volume at 12 weeks in 86% of pts. Tucatinib showed a high level of activity when combined with paclitaxel/trastuzumab/pertuzumab, but the combination is not feasible. Table: Number of pts with grade 2, 3, and 4 LFT elevations by treatment schedule (highest grade per patient per event, ALT or Treatment scheduleGrade 2 LFT elevationGrade 3 LFT elevationGrade 4 LFT elevationTucatinib 300 mg BID030Tucatinib 250 mg BID210Tucatinib 150 mg BID days 1-28 followed by 250 mg BID days 29 to 84112 Citation Format: David A Potter, Erin Roesch, Christina Yau, Ruixiao Lu, Denise Wolf, Susan Samson, Debra Stafford, Kathy S Albain, Claudine Isaacs, Meghana Trivedi, Douglas Yee, Judy Boughey, Alexandra Thomas, A. Jo Chien, Nola Hylton, Wen Li, Angela DeMichele, Jane Perlmutter, W. Fraser Symmans, Dawn L Hershman, Michelle Melisko, Laura J van 't Veer, Amy Wilson, Smita M Asare, Donald A Berry, Richard Schwab, Hope S Rugo, Laura J Esserman. Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD8-07.
Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial
Kyalwazi, Beverly , Olopade, Olufunmilayo, Chien, A. Jo , Forero‐Torres, Andres , Ellis, Erin M. , Albain, Kathy S. , Haley, Barbara , Elias, A. , Clark, Amy S. , Nanda, Rita , Yung, Rachel L. , Edmiston, Kristen K., Viscusi, Rebecca K., Northfelt, Donald W. , Khan, Qamar J. , Sanil, Ashish, Asare, Smita , Wilson, Amy , Hirst, Gillian L. , Melisko, Michelle , Perlmutter, Jane , Rugo, Hope, Symmans, Fraser, Veer, Laura van ‘t , Berry, Donald A. , Hirst, Gillian L , Yau, Christina , Olopade, Olufunmilayo I. , Wallace, Anne M. , Pusztai, Lajos , Ellis, Erin, Blaes, Anne , Boughey, Judy C. , Isaacs, Claudine , Han, Hyo S , Tripathy, Debu , Berry, Scott , Hylton, Nola M. , Symmans, W. Fraser , Veer, Laura J. van’t , Esserman, Laura J.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: GS4-02-GS4-02

10.1158/1538-7445.sabcs21-gs4-02 Get It

Abstract Background Transcriptomic immune-related gene signatures have been associated with achievement of pathologic complete response (pCR) and prognosis in the neoadjuvant setting. I-SPY 2 is a multicenter, phase 2 platform trial using response-adaptive randomization within subtypes defined by receptor status (HR/HER2) and MammaPrint (MP) risk to evaluate novel agents as neoadjuvant therapy for women with high-risk breast cancer. Given racial disparities in mortality from breast cancer and the paucity of racial demographic data from clinical trials, we aimed to evaluate the association between racial groups and baseline characteristics, including expression-based subtypes and immune signatures, treatment response, and prognosis of patients enrolled in the I-SPY 2 TRIAL. Methods Our study population included 990 I-SPY 2 patients. 15 patients identified as part of a racial group with &lt;10 patients enrolled in the trial and were excluded from analysis. Pre-treatment expression data was available for 971 patients. Follow-up data was available for 907 patients; median follow-up time of 4.4 yrs. Chi-square test was used to assess associations between racial groups and pre-treatment SBR grade, HR/HER2 defined subtypes, intrinsic subtype (defined by BluePrint 80-gene molecular subtyping) and residual cancer burden (RCB) class. Logistic regression was used to evaluate race association with pCR. Cox proportional hazard modeling was used to assess the association between racial groups and event free survival (EFS) in a univariate setting, adjusting for pCR status. Association between racial groups and 28 expression signatures related to immune, proliferation, ER and HER2 pathway was analyzed using ANOVA with post-hoc Tukey test in the overall population and in each receptor subtype. Results Of 975 patients included in our analysis, 787 (81%) were White, 68 (7%) were Asian, and 120 (12%) were Black or African American. No significant associations between race and pre-treatment SBR grade (p=0.49), HR/HER2 defined subtypes (p=0.09), or expression-based subtypes (p=0.25) were observed. pCR rates do not significantly differ by racial groups (Odds ratio of pCR relative to White: 1.00 for Asian and 0.89 for Black or African American); and no significant differences in RCB class distribution by race was observed (p=0.88). Event free survival was not associated with patient racial group in a univariate Cox model (Hazard ratio relative to White: 1.10, p=0.73 for Asian and 1.37, p=0.13 for Black or African American). Among the 28 expression signatures evaluated, four were differentially expressed among racial groups within the overall population (F-test p&lt;0.05): IFN module, B cell signature, Dendritic cell signature, and Mitotic score. Pairwise comparisons between racial groups with post-hoc Tukey test identified significant differences in IFN module expression between Black or African American vs. White (p=0.019) and Dendritic cell signature expression between Asian vs White (p=0.047). Among patients in the TNBC subtype, three signatures (dendritic cell signature, macrophage signature and ERBB2 module) were differentially expressed between Black or African American and White patients (p=0.002, 0.016 and 0.007). Conclusion Our analysis demonstrates that among women with high risk breast cancer, race does not affect subtype specific response rates nor event free survival. Distribution of subtypes previously shown to be associated with pCR in the I-SPY2 trial did not significantly differ among racial groups indicating race is less likely than tumor biology to predict response. The decreased expression of immune signatures observed in Black or African American women with TNBC suggests possible differential sensitivity to immunotherapy plus combination chemotherapy. Tumor immune multiplex studies are underway to further investigate. Citation Format: Beverly Kyalwazi, Christina Yau, Olufunmilayo Olopade, A. Jo Chien, Anne Wallace, Andres Forero-Torres, Lajos Pusztai, Erin Ellis, Kathy Albain, Anne Blaes, Barbara Haley, Judy Boughey, Anthony Elias, Amy Clark, Claudine Isaacs, Rita Nanda, Hyo Han, Rachel Yung, Debu Tripathy, Kristen Edmiston, Rebecca Viscusi, Donald Northfelt, Qamar Khan, Ashish Sanil, Scott Berry, Smita Asare, Amy Wilson, Gillian Hirst, Nola Hylton, Michelle Melisko, Jane Perlmutter, Hope Rugo, Fraser Symmans, Laura van ‘t Veer, Donald Berry, Laura Esserman. Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr GS4-02.
Human outgrowth knee fibroblasts from patients undergoing total knee arthroplasty exhibit a unique gene expression profile and undergo myofibroblastogenesis upon TGFβ1 stimulation
Bayram, Banu , Thaler, Roman , Bettencourt, Jacob W. , Limberg, Afton K. , Sheehan, Kevin P., Owen, Aaron R. , Berry, Daniel J., Wijnen, André J. van , Dudakovic, Amel , Berry, Daniel J. , Sanchez-Sotelo, Joaquin, van Wijnen, Andre J , Abdel, Matthew P , Berry, Daniel J , Berry, Daniel J., Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Abdel, Matthew P.

Mayo Clinic

Journal of Cellular Biochemistry | February 28, 2022 | Volume: 123 | Issue: 5 | Pages: 878-892

10.1002/jcb.30230 | PMID 35224764 Get It

AbstractArthrofibrosis is characterized by excessive extracellular matrix (ECM) deposition that results in restricted joint motion after total knee arthroplasties (TKAs). Currently, treatment options are limited. Therefore, an in vitro model of knee‐related myofibroblastogenesis is valuable to facilitate investigation of the arthrofibrotic process, diagnostic and therapeutic options. In this study, we obtained intraoperative posterior capsule (PC), quadriceps tendon (QT), and suprapatellar pouch (SP) tissues from the knees of four patients undergoing primary TKAs for osteoarthritis. From these tissues, we isolated primary cells by the outgrowth method and subsequently characterized these cells in the absence and presence of the pro‐myofibroblastic cytokine, transforming growth factor beta 1 (TGFβ1). Light microscopy of knee outgrowth cells revealed spindle‐shaped cells, and immunofluorescence (IF) analysis demonstrated staining for the fibroblast‐specific markers TE‐7 and vimentin (VIM). These knee outgrowth fibroblasts differentiated readily into myofibroblasts as reflected by enhanced α‐smooth muscle actin (ACTA2) mRNA and protein expression and increased mRNA expression of collagen type 1 (COL1A1) and type 3 (COL3A1) with collagenous matrix deposition in the presence of TGFβ1. Outgrowth knee fibroblasts were more sensitive to TGFβ1‐mediated myofibroblastogenesis than adipose‐derived mesenchymal stromal/stem cells (MSCs). While outgrowth knee fibroblasts isolated from three anatomical regions in four patients exhibited similar gene expression, these cells are distinct from other fibroblastic cell types (i.e., Dupuytren's fibroblasts) as revealed by RNA‐sequencing. In conclusion, our study provides an in vitro myofibroblastic model of outgrowth knee fibroblasts derived from patients undergoing primary TKA that can be utilized to study myofibroblastogenesis and assess therapeutic strategies for arthrofibrosis.